Physician profile
Pushpinder Singh
NPI 1326073552
$1,768.24
in general payments reported to CMS, 2019-2025
23 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $24.83 · 2021: $395 · 2022: $183 · 2023: $226 · 2024: $252 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $969.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $193.51 | 2023-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $185.33 | 2022-2025 | Ubrelvy |
| Glaxosmithkline, LLC. | $174.78 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.65 | 2021 | |
| Xeris Pharmaceuticals, INC. | $135.00 | 2025 | Recorlev |
| Indivior INC. | $134.07 | 2023-2025 | Sublocade |
| Astellas Pharma US INC | $109.83 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $107.34 | 2019 | |
| Orexo US, INC. | $84.14 | 2021-2025 | Zubsolv |
| Lilly USA, LLC | $63.23 | 2023 | Mounjaro |
| Novo Nordisk INC | $61.32 | 2021-2024 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $61.17 | 2022-2025 | |
| Dexcom, INC. | $61.04 | 2021-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $56.27 | 2024 | Zerbaxa, Dificid |
| Allergan, INC. | $44.55 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $24.90 | 2024 | Nuzyra |
| Abbott Laboratories | $20.90 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $20.57 | 2024 | Rexulti |
| Exact Sciences Corporation | $19.53 | 2023 | Cologuard Collection Kit |
| Bardy Diagnostics, INC. | $18.55 | 2022 | |
| Alk-Abello, INC | $18.17 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $17.63 | 2024 | |
| Depuy Synthes Sales INC. | $12.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pushpinder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.